Skip to main

Repatriation Pharmaceutical Benefits Scheme (Australian Participants in British Nuclear Tests) 2006 (No. R33 of 2006)

No longer in force
Administered by
  • Department of Veterans' Affairs

This item is authorised by the following title:

Superseded version
F2007L0019925 January 2007 - 31 March 2012

This instrument was approved by the Minister for Veterans' Affairs on 3 January 2007 (see Supporting Material).


Downloads

Access downloadable documents for version effective 25 January 2007 - 31 March 2012

Legislative instrument

Explanatory statement

Supporting material

Incorporated by reference

  • Australian Pharmaceutical Formulary (including previous editions): paragraph 33

  • Authority Prescription Form, approved under subregulation 13(2) of the National Health (Pharmaceutical Benefits) Regulations or under paragraph 14 of declaration No.PB 10 of 1993 made under subsection 85(2) of the National Health Act 1953*;: paragraph 3

  • British Pharmacopoeia (including previous editions): paragraph 33

  • European Pharmacopoeia: paragraph 33

  • Extra Pharmacopoeia: Paragraph 33

  • Pharamaceutical Codex (including previous editions): paragraph 33

  • Pharmaceutical Benefits Schedule made under the National Health Act 1953: paragraph 3

  • Pharmaceutical Benefits Scheme made under the National Health Act 1953: paragraph 3

  • Pharmaceutical Texts of International Standing similar to: the Extra Pharmacopoeia, European Pharmacopoeia, and the United States Pharmacopoeia: paragraph 33

  • Pharmacopoeia: paragraph 33

  • Prescribed Pharmacology text of international standing: paragraph 33

  • Repatriation Health Card - For Specific Conditions: paragraph 3

  • Repatriation Pharmaceutical Benefits Scheme Schedule prepared by the Department of Veterans' Affairs dated 1 February 2002 (VEA RPBS) : paragraph 3

  • Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners, ISSN 1037-3667 dated 1 February 2002: paragraph 3

  • Standard Prescription Form approved under paragraph 19(1)(a) of the National Health (Pharmaceutical Benefits) Regulations: paragraph 3

  • Treatment Principles (Australian Participants in British Nuclear Tests) 2006 : paragraph 3

  • United States Pharmacopoeia: paragraph 33